Clinical Trials Browser

Completed × Triple Negative Breast Neoplasms × talazoparib × Clear all

NCT04134884 2024-03-22

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02401347 2023-02-21

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Phase 2 Completed

21 enrolled 12 charts

Triple Negative Breast Neoplasms